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Summary Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with
a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial.
On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the clinical and
endocrinological responses to treatment in 45 assessable patients. The response rate to Zoladex in this series
was 31% and the ER status of the primary tumour was predictive of a response to the luteinising hormone-
releasing hormone.
In studies in the female rat, it has been shown that
luteinising hormone-releasing hormone (LH-RH)
agonists can suppress ovarian activity reducing
circulating levels of oestradiol and thus producing a
diminution in size of oestrogen-dependent target
tissues (Maynard & Nicholson, 1979). Such effects
in animals are accompanied by a reduction in
size of oestrogen receptor positive dimethyl-
benzanthracine (DMBA) induced mammary tumours
(Nicholson & Maynard, 1979).
Recent clinical studies in premenopausal patients
with metastatic breast cancer have produced
encouraging results when one such agent (Buserelin,
Hoe 766) was used alone and in combination with
the anti-oestrogen Tamoxifen. In this study the
combination of LH-RH agonist with Tamoxifen
was not recommended due to the observation that
unpredictable endocrinological responses, overriding
the LH-RH induced hypothalamic-pituitary
suppression, occurred when these two agents were
combined (Klijn, 1984).
Oophorectomy has become the mainstay of
treatment for premenopausal advanced breast
cancer since its introduction at the end of the last
century. This treatment has the disadvantage that
only a minority of patients will respond (Kennedy
et al., 1964) and for those not responding there is
additional treatment morbidity without benefit for
the patient. Recently receptor assays have assisted
prediction of hormonal responsiveness in metastatic
breast cancer but are rarely used exclusively to plan
treatment in clinical practice. For these reasons less
invasive methods of attaining a hormonal response
in advanced breast cancer have been sought. We
present the preliminary results from the use of an
LH-RH agonist (ICI 118630, Zoladex) in pre-
menopausal advanced breast cancer.
Patients and methods
All patients selected for study had histologically
proven locally advanced (greater than 5 cm
maximum diameter) breast cancer (n= 14) or
metastases confirmed by skeletal survey and isotope
scans (n=39). Informed consent was obtained from
all patients prior to therapy and no patient had
received previous endocrine or cytotoxic treatment
for their primary tumour or metastatic lesions.
Zoladex (ICI 118630) was administered by daily s.c.
injection to the first 27 patients studied and by
monthly depot formulation to the following 26
patients.
Daily subcutaneous therapy
Treatment was initiated immediately after con-
firmation of the diagnosis and thus at differing
times throughout thp menstrual cycle. Of the 27
patients treated with daily s.c. injections the first
5 patients received 500 4g daily and the following
22 patients received 1000 4g daily throughout
treatment. Nine of the 21 patients assessable for
response commenced therapy in the luteal phase of
the menstrual cycle and 12 in the follicular phase.
Blood samples were withdrawn for endo-
crinological studies prior to starting treatment and
were repeated at 1, 2 and 4h after the initial
injection on the first day of treatment. Assays for
Follicle Stimulating Hormone (FSH), Luteinising
Hormone (LH), oestradiol and progesterone were
performed at the Tenovus Institute, Cardiff. A
further venous blood sample was withdrawn for all
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endocrine studies on days 2, 3, 5 and 7 of
treatment, and thereafter at weekly intervals
throughout therapy. Sequential samples were
withdrawn 24h after the previously administered
dose of the LH-RH agonist.
Monthly depot therapy
All 26 patients receiving the depot formulation
(3.6 mg subcutaneous/month) started treatment in
the follicular phase of the menstrual cycle.
Sequential endocrine studies including FSH, LH,
oestradiol and progesterone were again recorded
prior to treatment and at regular intervals
throughout therapy (pre-treatment, days 2, 3, 5 and
7 and thereafter at weekly intervals).
To date 53 patients have been entered into the
study, using daily or monthly administered
Zoladex, with a minimum follow up of 6 months.
The protocol of this phase one study demanded a
change of therapy in the event of aggressive disease
continuing to rapidly progress before the minimum
time necessary to achieve ovarian suppression.
Eight patients therefore have been excluded from
analysis and have not been considered further,
leaving 45 patients assessable for a response to
therapy. Of the eight exclusions, two patients
moved out of the area and so received alternative
treatments, the remaining six patients were changed
to non-endocrine therapies due to rapid sympto-
matic disease progression before completing two
months on Zoladex. All these patients had hepatic
or cerebral involvement and it is accepted by the
authors that they may well have been unlikely to
respond to endocrine manipulation.
The patients' age, disease status and sites of
metastases at the presentation of advanced disease
are shown in Table Ia, lb.
Assessment, follow-up and criteria for response
Initial assessment included a full clinical examina-
tion with documentation of all measurable local
disease and photography when appropriate. A
limited skeletal survey including views of chest,
skull, dorso-lumbar spine and pelvis was obtained
in all patients. Isotope liver scans were performed
only when clinically indicated. Haematological tests
included a full blood count, ESR, urea and
electrolytes, and liver function tests. The Karnofsky
performance status was recorded prior to and
throughout therapy.
The UICC criteria (Hayward et al., 1977)
demanding a 50% reduction in measurable tumour
or objective radiographic evidence of regression in
evaluable but non measurable disease sites (e.g.
bone and lung) were employed throughout the
study period to assess treatment response. The
British Breast Group stipulation that any remission
should be maintained for at least six months before
classifying as a response was also adhered to
(British Breast Group, 1974).
Table Ia Patients' tumour stage and sites of distant
metastases. Daily subcutaneous Zoladex.
Patient Age Stage Metastases
L.G. 46 4 Lung, bone
D.K. 48 3 Local
A.H. 45 4 Bone
M.D. 47 4 Bone
G.B. 32 4 Lung
S.M. 47 4 Bone
M.M. 43 3 Local
P.J. 39 4 Local, bone
A.M. 39 4 Local, bone
L.S. 40 3 Local
S.G. 40 3 Local
M.B. 45 4 Lung, bone
C.G. 44 4 Lung, bone
I.E. 47 4 Local, bone
I.H. 48 4 Local, bone, liver
L.H. 47 4 Lung
W.G. 47 3 Local
JJ. 43 4 Bone
M.S. 45 4 Lung, bone
B.S. 50 4 Lung, bone
P.P. 45 3 Local
Table lb Patients' tumour stage and sites of distant
metastases. Monthly depot formulation.
Patient Age Stage Metastases
G.B. 46 4 Lung, local
S.H. 46 4 Bone, liver, local
H.F. 49 3 Local
R.L. 47 4 Bone, local
P.C. 50 4 Lung, bone
J.S. 49 3 Local
J.K. 46 4 Lung, local
W.R. 49 3 Local
P.P. 46 4 Lung, local
B.S. 38 4 Lung, bone, liver
T.S. 43 3 Local
A.H. 43 4 Bone
M.S. 55 4 Bone, local
J.C. 49 4 Bone, visceral
J.E. 43 3 Local
F.C. 44 4 Bone
S.C. 45 3 Local
A.S.1 37 4 Visceral, bone
J.H.1 45 4 Bone, local
J.H.2 41 4 Bone, local
A.W. 29 4 Bone
R.W. 44 3 Local
C.W. 35 4 Lung
A.S.2 48 3 LocalZOLADEX IN ADVANCED BREAST CANCER 631
In the first 27 patients showing disease
progression on Zoladex surgical oophorectomy was
routinely performed in all cases fit for this
procedure (n=26). Patients were reviewed at
monthly intervals and routine haematological tests
were repeated at each attendance. Skeletal surveys
were repeated at three monthly intervals or more
frequently if clinically indicated.
Results
Endocrinological
Daily subcutaneous therapy The effects of daily s.c.
injections of Zoladex on circulating concentrations
of LH, FSH, oestradiol and progesterone are
shown in Figures 1 and 2.
Within 16h of the administration of Zoladex
there was a substantial rise in the plasma
concentrations of both LH and FSH (Figure 1). On
continued treatment however, basal levels of these
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hormones decreased and were associated with an
eventual fall in circulating concentrations of both
oestradiol and progesterone in all but two patients
(Figure 2). With the exception of these two
patients, suppression of both pituitary and ovarian
hormones was maintained during active therapy
with Zoladex. The levels of oestradiol and
progesterone found in patients with complete
ovarian suppression were equivalent to those seen
in either oophorectomised or postmenopausal
patients with advanced breast cancer.
In the two patients with recurrent peaks of
oestradiol basal levels of cirulating LH, FSH and
progesterone were maintained throughout therapy
(Figure 3).
No differences in endocrine response were
observed between patients receiving doses of 500 or
1000pg daily (not illustrated).
In those patients commencing treatment in the
follicular phase of the cycle (n= 12) castrate levels
of serum oestradiol and progesterone were attained
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Figure 1 Long-term effects of daily ICI 118630 on plasma LH and FSH in patients with advanced breast
cancer (mean+s.e.).
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Figure 2 Long-term effects of daily ICI 118630
A =postmenopausal, B =oophorectomised.
in 9 patients after one month's therapy. All 9
patients commencing treatment in the luteal phase
showed some evidence of cyclical oestradiol
production during the second month of treatment
before castrate levels were achieved. These
oestradiol peaks were, however, suppressed when
compared with the mid cycle oestradiol levels found
in control patients.
Monthly depot therapy Similar endocrinological
results were obtained using the monthly depot
formulation with 'castrate' levels of progesterone
and oestradiol achieved in 21 of 24 assessable
patients after the first month on therapy (not
illustrated). The three patients refractory to the
depot dosage of the LH-RH agonist used exhibited
recurrent, though suppressed, peaks of oestradiol
throughout a maximum of 3 months active therapy.
Oestradiol concentrations were equivalent to those
*ime (days)
on plasma oestradiol and progesterone (mean +s.e.).
observed in patients starting daily subcutaneous
therapy during the luteal phase of the menstrual
cycle. Interestingly one of these patients with
incomplete ovarian suppression had ceased to
menstruate and showed objective signs of response
(sclerosis in lytic bone metastases) during the first
three months of therapy despite recurrent oestradiol
peaks. This response was not maintained for 6
months and no response was found to subsequent
oophorectomy (patient RL, Figure 2b).
Clinical response to Zoladex
The ER status, clinical response to Zoladex and
response to subsequent oophorectomy are shown in
Table Ila, b. Fourteen of the 45 patients in whom
disease was assessable on the clinical criteria used
(UICC, BBG) responded partially to treatment.
Three patients showed no evidence of disease
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Figure 3 Influence of daily ICI
oestradiol throughout therapy.
* 20
*16
1612T
U-
I
*4
40 60 80 100 120 140 160 180
Time (days)
118630 on plasma hormone levels in a patient showing recurrent peaks of
progression over 6 months therapy and in 28
patients disease progressed despite treatment.
Ten of the 14 patients showing a partial response
presented with bone metastases with additional
intra-abdominal involvement in two of these cases.
A further patient responding to Zoladex received
treatment for inoperable locally recurrent axillary
nodes and the remaining three responding patients
presented with stage III disease.
The oestrogen receptor status of the primary
tumours was available in 38 of the 45 assessable
patients. Nineteen patients were ER positive and 19
ER negative. Thirteen of 14 patients responding to
Zoladex were either ER positive (n=10) or ER
status unknown (n =3). The remaining eighteen
patients with ER negative primary tumours all
failed to respond (Table Ila, b).
Surgical oophorectomy after disease progression
was performed on 26 patients. Four patients
subsequently showed a response to oophorectomy
having failed to respond to Zoladex. In one of
these patients serum oestradiol had not been
suppressed to castrate levels after 6 months on
treatment (patient LH, Figure 3) and the remaining
three patients had progressed from Zoladex therapy
to oophorectomy after short periods of only one,
two and three months respectively.
No response to oophorectomy was observed in
20 patients who failed to respond to Zoladex, in
two of these patients disease remained static at 6
months. A further two patients' responses to
oophorectomy after failing to respond to Zoladex
were not assessable due to the addition of radio-
therapy to bone metastases immediately post-
operatively in one case and surgical excision of all
assessable local disease in the remaining patient
with stage III disease.
Two patients have undergone oophorectomy
after responding to Zoladex for periods of 12 and
13 months respectively. No subsequent response
was observed in either case.
The overall response rate to Zoladex in this series
E
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Table Ila Oestrogen receptor status and response to daily subcutaneous
treatment.
Subsequent
Response to response to
ER Zoladex Oophorectomy
Patient status (n=21) (n= 18)
L.G. + Nil Nil
D.K. + Stat
A.H. + Nil PR
M.D. - Nil Nil
G.B. Nil Nil
S.M. + PR Stat
M.M. - Nil Nil
P.J. - Nil Nil
A.M. - Nil Stat
L.S. ? Nil Nil
S.G. ? Nil Nil
M.B. - Nil Nil
C.G. + PR Nil
I.E. + Nil PR
I.H. + Nil PR
L.H. - Nil PR
W.G. - Nil Nil
JJ. + Nil Unassessable
M.S. ? Nil Nil
B.S. + PR
P.P. ? PR Unassessable
Total showing + or unknown 4 3
partial response - 0 1
of patients, when 8 patients are excluded due to
loss of follow-up or the addition of alternative
treatments prior to 2 months Zoladex therapy, is
therefore 31%.
Side effects
Side effects relating to treatment with the LH-RH
agonist were minimal and included cessation of
menstruation in association with suppressed
oestradiol, hot flushes (20 patients) and occasional
nausea. All suppressed patients had ceased to have
normal menstrual periods by two months after
initiation of therapy although 7 patients
experienced menstrual spotting after the second
month on Zoladex.
Tumour flare, although difficult to assess in
rapidly progressing advanced disease, was not
observed.
Discussion
It is apparent from this and other preliminary
clinical studies that LH-RH agonists are capable of
achieving responses in premenopausal patients with
advanced breast cancer. The endocrinological
response to Zoladex, although at present not
achieved as rapidly, is quantitatively similar to that
seen after surgical oophorectomy.
The initiation of daily treatment in the luteal
phase of the menstrual cycle resulted in a prolong-
ation of the time necessary to achieve complete
ovarian suppression, as has been suggested in other
clinical studies (Klijn, 1984). This disadvantage may
have clinical implications in rapidly progressing
disease.
The explanation for the inability of the LH-RH
agonist to achieve complete ovarian suppression in
the five patients refractory to the dosage used is not
at present clear. Two patients administered their
own daily subcutaneous therapy but were observed
to be competent at this technique. In the remaining
three patients the monthly depot formulation was
administered by one author in the outpatient clinic.
The failure of the LH-RH agonist did not appear
to be related to either premenopausal age or body
weight. In all five patients serum progesterone was
suppressed to basal levels on continued treatment,
an indication that anovulation had occurred.
It is of interest that one patient with incomplete
ovarian suppression showed evidence of an early
response to treatment in bone metastases after three
months therapy, raising the possibility of a direct
antitumour effect mediated by the LH-RH agonist.ZOLADEX IN ADVANCED BREAST CANCER 635
Table Ilb Oestrogen receptor status and response to monthly
subcutaneous treatment.
Subsequent
Response to response to
ER Zoladex Oophorectomy
Patient status (n=24) (n=7)
G.B. - Nil Nil
S.H. ? Nil Nil
H.F. - Nil Nil
R.L. + Nil Nil
P.C. - Nil
J.S. - Stat
J.K. + Nil Nil
W.R. - Stat
P.P. - Nil Nil
B.S. - Nil
T.S. + Nil Nil
A.H. ? PR -
M.S. + PR -
J.C. + PR -
J.E. + PR -
F.C. + PR -
J.C. + PR -
A.S.1 + PR -
J.H.1 + PR -
J.H.2 - PR -
A.W. - Nil -
R.W. ? PR -
C.W. - Nil -
A.S.2 - Nil -
Total showing + or unknown 9 0
partial response - 1 0
Such an effect has been suggested by an in vitro
study showing a retardation in growth of cultured
mouse mammary tumour cells after the application
of an LH-RH agonist (Corbin, 1982). Further
evidence for a direct antitumour effect is suggested
by isolated reports of responses occurring in post-
menopausal women receiving treatment (Harvey et
al., 1981). An alternative explanation is that
complete ovarian suppression may not be necessary
to achieve objective remissions in all cases.
Four patients responded to oophorectomy
without an apparent previous response to Zoladex.
One of these patients, with lung metastases, was
refractory to the dosage of the LH-RH agonist
administered with serum oestradiol continuing to
peak after six months therapy. This patient
remained asymptomatic throughout treatment with
Zoladex. The remaining three patients with bone
metastases had received treatment for a maximum
of only 12 weeks. The clinical responses in all
patients were assessed strictly and at short intervals
and so with continued therapy a response may have
occurred with the use of the LH-RH agonist alone
in these three patients. A retrospective review of the
X-rays in two of the three patients responding to
oophorectomy would suggest to the authors that a
mis-classification of disease progression on Zoladex
may have occurred as early signs of sclerosis were
present in lytic metastases at the time of
oophorectomy. Certainly their hormone profiles
were comparable with oophorectomised patients.
The response rate to Zoladex of 31% is
comparable to our previous experience using
surgical oophorectomy and is lower than other
reported series as our criteria exclude short
remissions of less than six months duration.
The time course to response on Zoladex was
similar to that found after surgical oophorectomy
in all patients with stage III disease as was the case
in those patients with bone metastases. However, in
the latter situation objective responses are difficult
to assess during the early stages of treatment.
The side effects relating to therapy were minimal
and all patients tolerated treatment well.
Although patient numbers are small, it appears
that the absence of the oestrogen receptor in the
primary tumour is predictive of a failure to respond
to the administration of Zoladex.
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